Azithromycin inhibits mucus hypersecretion from airway epithelial cells

Area of Science:

• Respiratory Medicine
• Pharmacology
• Cell Biology

Background:

• Mucus hypersecretion is a hallmark of various respiratory diseases.
• Goblet cell hyperplasia and metaplasia contribute to excessive mucus production.
• Macrolide antibiotics are known for their anti-inflammatory properties.

Purpose of the Study:

• To investigate the in vivo and in vitro effects of azithromycin (AZM) on mucus hypersecretion.
• To compare AZM's efficacy with other antibiotics like clarithromycin (CAM), josamycin (JM), and ampicillin (ABPC).
• To elucidate the mechanisms underlying AZM's impact on airway epithelial mucus production.

Main Methods:

• In vivo studies involved inducing mucus hypersecretion in rats using ovalbumin (OVA) or lipopolysaccharides (LPS).
• Oral administration of macrolides (AZM, CAM, JM) and ampicillin (ABPC) was assessed for their effects on mucus production.
• In vitro studies utilized NCI-H292 and human nasal epithelial cells to evaluate AZM's direct impact on MUC5AC secretion and mRNA expression induced by TNF-α.

Main Results:

• Oral AZM and CAM significantly inhibited OVA- and LPS-induced mucus production in rats, while JM and ABPC had no effect.
• In vitro, AZM and CAM markedly reduced TNF-α-induced MUC5AC secretion from NCI-H292 cells.
• AZM also inhibited TNF-α-induced MUC5AC secretion and mRNA expression in human nasal epithelial cells.

Conclusions:

• Azithromycin (AZM), a 15-member macrolide, demonstrates direct inhibitory effects on mucus secretion from airway epithelial cells.
• AZM's ability to reduce MUC5AC production suggests its therapeutic potential for conditions characterized by mucus hypersecretion.
• These findings support the use of AZM in managing allergic inflammation and LPS-stimulated mucus overproduction.